BC Extra | Feb 1, 2020
Company News

FDA continues its run of indication-first approvals with Aimmune’s peanut allergy therapy

FDA’s approval of Aimmune’s peanut allergy therapy continues the momentum of what’s expected to be a big year for approvals in indications with no available treatment options. The agency approved Palforzia Friday to reduce the...
BC Extra | Aug 23, 2019
Clinical News

Aug. 22 Clinical Quick Takes: Rituximab biosimilar meets endpoint; plus Aimmune, NKMax, Calibr

Rituximab biosimilar meets NHL endpoint  Amgen Inc. (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) said top-line results from the Phase III JASMINE study showed rituximab biosimilar (ABP 798) met the trial's primary endpoint of clinical equivalence to...
Items per page:
1 - 2 of 2